에 대한 최신 뉴스 JBT Marel (NYSE:JBTM) 주식

JBT Marel

JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.

JBT Marel Corp

UBS analyst Jay Sole maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $330 to $290.

News

Price Target

Analyst Ratings

LULU

UBS Maintains Neutral on Lululemon Athletica, Lowers Price Target to $290

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) has outperformed the market over the past 20 years by 4.93% on an annualized basis producing an average annual return of 13.27%. Currently, F5 has a market capitalization of $17.06 billion. 
Buying $100 In FFIV: If an investor had bought $100 of FFIV stock 20 years ago, it would be worth $1,165.01 today based on a price of $294.51 for FFIV at the time of writing.
<h3>F5's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749220217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FFIV

Here's How Much You Would Have Made Owning F5 Stock In The Last 20 Years

Rumors

IPOs

OMDA

Omada Health IPO Indicating $25.07/Share On 190K Shares; IPO Priced At $19/Share

Omada Health IPO Indicating $30.25/Share On 170k Shares; IPO Priced At $19/Share

BTIG analyst Janine Stichter maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and lowers the price target from $420 to $405.

BTIG Maintains Buy on Lululemon Athletica, Lowers Price Target to $405

Bernstein analyst Peter Weed downgrades CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Outperform to Market Perform and maintains the price target from $371 to $371.

Downgrades

CRWD

Bernstein Downgrades CrowdStrike Holdings to Market Perform, Maintains Price Target to $371

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Loop Capital analyst Alton Stump downgraded the rating for McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Buy to Hold and lowered the price target from $346 to $315. McDonald&#8217;s shares closed at $308.98 on Thursday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Eric Wolfe downgraded American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) from Buy to Neutral and maintained the price target of $41. American Homes 4 Rent shares closed at $36.87 on Thursday. <a href="https://www.benzinga.com/quote/AMH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MCD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MCD/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-1024x598.png" alt="" class="wp-image-941250" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092825/image-99.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Markets

This McDonald's Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday

Walt Disney Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) <a href="https://www.benzinga.com/topic/walt-disney-world" target="_blank" rel="noreferrer noopener">domestic theme parks</a> have been the growth engine for tourism, job creation, and tax revenue.
Disney Parks &amp; Resorts generated a historic $67 billion annual economic impact from coast to coast. And they support over 403,000 direct and indirect jobs, not just in California and Florida, but <a href="https://thewaltdisneycompany.com/disney-parks-economic-impact/" target="_blank" rel="noreferrer noopener">all 50 states</a>.
According to Tourism Economics, an Oxford Economics company, Disneyland Resort in Anaheim, California, generates $16.1 billion in annual economic impact across Southern California and supports more than 102,000 jobs in the region.
Also Read: <a href="https://www.benzinga.com/25/05/45266716/disneys-streaming-gains-park-strength-cash-surge-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">Disney&#8217;s Streaming Gains, Park Strength, Cash Flow Drive Analyst Optimism</a>
The company&#8217;s plan to &#8216;turbocharge&#8217; the growth of Disney&#8217;s domestic parks will increase capital expenditures in the U.S. to $30 billion through 2033. The plans include:
<ul class="wp-block-list">
<li>Expanding the Magic Kingdom</li>
<li>Creating a new Tropical Americas land in Disney&#8217;s Animal Kingdom</li>
<li>Launching a land based on Pixar Animation Studios&#8217; Monsters, Inc at Disney&#8217;s Hollywood Studios</li>
<li>Doubling the size of Avengers Campus at Disney&#8217;s California Adventure park.</li>
</ul>
Walt Disney reported <a href="https://www.benzinga.com/25/05/45251203/disney-rides-strong-subscriber-growth-and-movie-hits-lifts-forecast-with-1-billion-streaming-goal" target="_blank" rel="noreferrer noopener">fiscal second-quarter 2025</a> revenue growth of 7% to $23.62 billion. It beat the analyst consensus of $23.14 billion driven by its Entertainment and Experiences businesses. Adjusted EPS of $1.45 beat the analyst consensus of $1.20.
Disney&#8217;s experiences division benefited from visitors to parks in California and Florida, holiday package sales, and the launch of the Disney Treasure ship in December.
Disney and Miral, a creator of immersive destinations and experiences, announced a deal to build a theme park resort on Yas Island in Abu Dhabi, United Arab Emirates.
For fiscal 2025, Disney projected an adjusted EPS&nbsp;of $5.75, an increase of 16% over fiscal 2024 versus a $5.44 analyst estimate (compared to the prior estimate of high-single-digit&nbsp;growth).
Price Actions: DIS stock is up 1.23% at $113.90 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/05/45692478/disney-adds-fan-perks-to-win-over-us-viewers-in-streaming-battle" target="_blank" rel="noreferrer noopener">Disney Adds Fan Perks To Win Over US Viewers In Streaming Battle</a></li>
</ul>
Image: Shutterstock

Disney Parks Drive $67 Billion In US Economic Impact, Support Over 400K Jobs Nationwide

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Friday.
Shares of Quanex Building Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) rose sharply during Friday's session after the company reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/NX">financial results</a>.
Quanex Building reported quarterly earnings of 60 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $452.50 million which beat the analyst consensus estimate of $439.30 million.
Quanex Building Products shares jumped 23.4% to $21.10 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Tango Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares jumped 27% to $4.4776.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) jumped 17.7% to $97.48 after gaining 168% on Thursday.</li>
<li>The Generation Essentials Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGE#NYSE">TGE</a>) rose 17% to $11.76.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) gained 15.2% to $15.94 after the company reported better-than-expected third-quarter sales results.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) rose 15.8% to $8.48.</li>
<li>Taseko Mines Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGB#NYSE">TGB</a>) gained 13.5% to $2.9450.</li>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) surged 13.2% to $6.78.</li>
<li>Byrna Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) rose 12.7% to $29.96. Byrna Technologies announced preliminary fiscal second quarter record revenues of $28.5 million.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) rose 11.7% to $18.74. Wolfe Research analyst Trevor Allinson initiated coverage on QXO with an Outperform rating and announced a price target of $44.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) gained 10% to $18.70.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) climbed 9.8% to $14.05.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 9.3% to $34.42.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) climbed 9.1% to $147.34.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) rose 8.2% to $17.78.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7.7% to $689.00.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) gained 6.6% to $198.94. AeroVironment will report its financial results for the fourth quarter after the market closes on Tuesday, June 24.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

APLD

AVAV

BYRN

COGT

CRCL

CRWV

LEGN

MANU

QBTS

RCAT

TNGX

TSSI

Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) <a href="https://www.benzinga.com/pressreleases/25/06/g45810251/arvinas-announces-submission-of-new-drug-application-to-u-s-fda-for-vepdegestrant-for-patients-wit" target="_blank" rel="noreferrer noopener">with its partner</a> Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
The application covers vepdegestrant for patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">endocrine-based therapy</a>.
This submission is based on Phase 3 VERITAC-2 trial results evaluating vepdegestrant versus fulvestrant.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651990/arvinas-touts-positive-data-from-potential-parkinsons-candidate-in-human-study-with-healthy-volunteers" rel="noreferrer noopener">Arvinas Potential Parkinson&#8217;s Treatment Shows Positive Data In Human Study</a>
At the American Society of Clinical Oncology, the companies shared detailed results from the Phase 3 VERITAC-2 trial.
These detailed results follow the March 2025 announcement of the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44255339/arvinas-pfizer-breast-cancer-drug-fails-to-show-progression-free-survival-benefit-in-trial" rel="noreferrer noopener">topline results from VERITAC-2</a>.
In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among patients with an estrogen receptor 1 (ESR1) mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant.
The median PFS was 5 months with vepdegestrant <a href="https://www.benzinga.com/pressreleases/25/05/g45709824/arvinas-and-pfizers-vepdegestrant-significantly-improves-progression-free-survival-for-patients-wi" target="_blank" rel="noreferrer noopener">versus 2.1 months with fulvestrant</a>.
The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant.
Vepdegestrant was generally well tolerated in the trial, with a safety profile consistent with that observed in previous studies, and mostly low-grade treatment-emergent adverse events (TEAEs).
Overall survival (OS), the key secondary endpoint in VERITAC-2, was immature at the time of the analysis, with less than a quarter of the required number of events having occurred.
Additional secondary endpoints include clinical benefit rate (CBR), objective response rate (ORR), and duration of response.
In patients with an ESR1 mutation, CBR was 42.1% with vepdegestrant versus 20.2% with fulvestrant, and ORR was 18.6% with vepdegestrant versus 4.0% with fulvestrant.
The median duration of response was not reached.
ARVN, PFE Price Action: ARVN stock is up 4.91% at $7.26, and Pfizer stock is up 1.79% at $23.25 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/sports/25/06/45812523/manchester-united-stock-jumps-after-q3-profit-turnaround-matchday-growth-and-stadium-plans" target="_blank" rel="noreferrer noopener">Manchester United Stock Jumps After Q3 Profit Turnaround, Matchday Growth, And Stadium Plans</a></li>
</ul>
Photo: jittawit21 via Shutterstock

Biotech

Health Care

General

ARVN

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

<a href="https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/">https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/</a>

PHGE

'Wall Street Sees 3,000% Upside as This $13M Biotech Tackles Medicine's Superbug Crisis (PHGE)'- The Finance Herald

UBS analyst Peter Grom maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Sell and lowers the price target from $54 to $52.

UBS Maintains Sell on General Mills, Lowers Price Target to $52

Investors have followed Michael Burry's trades ever since he predicted the financial crisis of 2008 and profited from it by taking up short positions. The man still known to many as "The Big Short" investor is making headlines for his bearish outlook on one of the world's biggest tech stocks. Benzinga examines why Burry has taken short positions on Nvidia (NASDAQ:<a href="https://www.benzinga.com/quote/NVDA"> NVDA</a>).
<a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45632498/nvidias-40-billion-oracle-win-may-trigger-a-chip-etf-rally">Nvidia</a> shares have spent much of the last 18 months on a bull run powered by AI's emergence as the world's hottest investment sector. As recently as May 2023, Nvidia shares were trading in the $35 range. Then it became clear that Nvidia's graphics processors and chipsets were mission-critical components in AI development, and the company's stock was off to the races.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Nvidia shares increased from around $40 in January 2024 to $147.16 by early November. The company's market cap grew to an astonishing $3 trillion, and CEO Jensen Huang achieved near celebrity status as his company gate-crashed the S&amp;P 500 Magnificent Seven. That kind of explosion in share price and market cap made Nvidia one of the biggest stories of 2024, but Burry knows what goes up must come down.
<a href="https://www.barchart.com/story/news/32563704/michael-burry-is-betting-against-nvidia-stock-should-you-follow-the-big-short-star-and-sell-nvda-now">Barchart</a> is reporting that Burry's Scion Asset Management has numerous put options in Nvidia. Beyond that, the water gets a little murky in terms of predicting Burry's long game. Barchart compiled the option data from Scion's March 13F filings, but those filings include multiple shorts. Scion is also betting against Alibaba (NYSE:<a href="https://www.benzinga.com/quote/BABA"> BABA</a>), Baidu, and Tripadvisor.com (NASDAQ:<a href="https://www.benzinga.com/topic/tripadvisor"> TRIP</a>). The filings only note that the combined total of Scion's shorts is $199 million.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
There is no information about expiration dates or strike prices, and the filings don't disclose whether Scion has long positions on Nvidia or the other stocks it's shorting. All this makes it difficult to decipher whether Burry has completely soured on Nvidia. President Donald Trump's tariffs have rattled multiple economic sectors, especially tech and retail, where Nvidia and<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45620670/alibaba-eyes-growth-in-other-markets-as-us-ties-strained-says-chairman"> Alibaba</a> operate.
Like many tech companies, Nvidia is heavily dependent on Chinese components, and jitters over the tariffs saw its shares slump to the $90 range in late March. Trump is still negotiating with China, and Nvidia has rebounded to $135.50 per share. The next shoe to drop will be quarterly earnings, which Burry may be expecting to fall short of projections.&nbsp;
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
So, the pressing question for investors is whether Burry is simply hedging with these short bets or believes Nvidia is overpriced and due for a correction. He has a proven knack for getting out of high-performing positions before the bottom drops, and these shorts could be part of that trend. However, the fact that Burry and Scion have $199 million in shorts spread across multiple positions may indicate that Burry is guarding against the downside.
With that said, Burry shorting Nvidia should give investors cause to assess their long-term positions and goals with this stock. In the meantime, keep your eyes peeled for Nvidia's earnings report and news on the tariff negotiations. Both of those will have a significant impact on Burry's next moves with Nvidia.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Personal Finance

Is The Bull Run Over For Nvidia– 'The Big Short' Investor Michael Burry Taking Up Short Positions

Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) today announced the expansion of its Capa&#xAE; caprolactone distribution network by establishing Jamplast as its exclusive distributor for Capa TP for bioplastics in the United States and Canada.
Jamplast, a leading plastic resin distributor of biopolymers, engineering polymers and commodity grade thermoplastics serving plastic processing manufacturers, will leverage the company's technical sales and marketing networks in North America to maximize the sales of Ingevity's Capa caprolactone products.
Ingevity's agreement with Jamplast is effective as of April 23, 2025.

NGVT

Ingevity Expands Capa Caprolactone Distribution Network By Establishing Jamplast As Exclusive Distributor For Capa TP For Bioplastics In US And Canada

WIIM

RBRK

RBRK stock has given up its prior gain. Rubrik shares were trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates. Also, the company raised its FY26 guidance above estimates.

Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) has outperformed the market over the past 10 years by 4.82% on an annualized basis producing an average annual return of 15.81%. Currently, Chipotle Mexican Grill has a market capitalization of $70.88 billion. 
Buying $1000 In CMG: If an investor had bought $1000 of CMG stock 10 years ago, it would be worth $4,321.31 today based on a price of $52.60 for CMG at the time of writing.
<h3>Chipotle Mexican Grill's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749219318_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

UBS analyst Karl Keirstead maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Neutral and lowers the price target from $85 to $80.

DOCU

UBS Maintains Neutral on Docusign, Lowers Price Target to $80

JMP Securities analyst Silvan Tuerkcan reiterates Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Market Outperform and maintains $15 price target.

Reiteration

SLDB

JMP Securities Reiterates Market Outperform on Solid Biosciences, Maintains $15 Price Target

UBS analyst Taylor McGinnis maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Buy and lowers the price target from $51 to $48.

BRZE

UBS Maintains Buy on Braze, Lowers Price Target to $48

UBS analyst Dennis Geiger maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $200 to $220.

TXRH

UBS Maintains Buy on Texas Roadhouse, Raises Price Target to $220

Press Releases

JBT Corporation Completes Settlement of its Voluntary Takeover Offer of Marel hf. and Commences Trading as JBT Marel Corporation

JBT Marel Announces Fourth Quarter and Full Year 2024 Earnings Conference Call Schedule

JBT Marel Corporation Reports JBT Standalone Fourth Quarter and Full Year 2024 Results, Provides Highlights on Marel's 2024 Results, and Establishes 2025 Guidance

JBT Marel Declares Quarterly Dividend

JBT Marel Announces First Quarter 2025 Earnings Release and Conference Call Schedule

JBT Marel Corporation Reports First Quarter 2025 Results

JBT Marel Corporation Declares Quarterly Dividend

JBT Marel Corporation Appoints James Pelletier as Executive Vice President and General Counsel

Comments

JBT Marel

뉴스

에 대한 최신 뉴스 JBT Marel (NYSE:JBTM) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌